SCHEMBL361109

SCHEMBL361109

CC(C)(C)OC(=O)Cc1n[nH]c(=O)c2nccnc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 3/20 0.39
MAPT P10636 1/20 0.38
TNKS O95271 1/20 0.34
PRMT5 O14744 1/20 0.33
WDR77 Q9BQA1 1/20 0.33
LMNA P02545 1/20 0.33
PARP1 P09874 2/20 0.32
HPGD P15428 1/20 0.32
KDM4E B2RXH2 1/20 0.32
KMT2A Q03164 1/20 0.32
CCNB2 O95067 1/20 0.32
CCNE2 O96020 1/20 0.32
CDK1 P06493 1/20 0.32
CDK4 P11802 1/20 0.32
CCNB1 P14635 1/20 0.32
CCND1 P24385 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
CCNB3 Q8WWL7 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15217593 0.84 SMN1; SMN2 (0.39) SMN1; SMN2ALDH1A1MAPTTNKSPRMT5
SCHEMBL15217600 0.84 SMN1; SMN2 (0.38) SMN1; SMN2ALDH1A1MAPTPRMT5WDR77
SCHEMBL9377801 0.83 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TNKSLMNAPARP1
SCHEMBL9378653 0.83 SMN1; SMN2 (0.51) SMN1; SMN2ALDH1A1TNKSLMNAPARP1
SCHEMBL15217619 0.78 SMN1; SMN2 (0.42) SMN1; SMN2ALDH1A1MAPTPRMT5WDR77
SCHEMBL15217609 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MAPTTNKSPRMT5
SCHEMBL15217613 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MAPTTNKSPRMT5
SCHEMBL15217622 0.78 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1MAPTPRMT5WDR77
SCHEMBL360658 0.77 LMNA (0.53) SMN1; SMN2ALDH1A1LMNAPARP1KDM4E
SCHEMBL24661307 0.76 SMN1; SMN2 (0.41) SMN1; SMN2ALDH1A1MAPTPRMT5WDR77

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2024-06-06 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
US-11730737-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2023-08-22 US disclosed
EP-4124620-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2023-02-01 EP disclosed
US-11529349-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-12-20 US disclosed
EP-3597650-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2022-09-07 EP disclosed
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2020-09-17 US disclosed
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-08-27 US disclosed
US-10639306-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-05 US disclosed
EP-3192796-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2019-09-04 EP disclosed
EP-2945934-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2015-11-25 EP disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
US-8916563-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-12-23 US disclosed
WO-2014113380-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-07-24 WO disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2013-08-29 US disclosed
EP-2593456-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2013-05-22 EP disclosed
WO-2012009553-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240180907-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-20200268755-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-20200289512-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-11529349-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-10639306-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-20130225592-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885
US-11730737-B2 Aldose reductase inhibitors and uses thereof ALDOA, AKR1B1, AKR1C2 SMN1; SMN2 2204/4885ALDH1A1 18/4885MAPT 1238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.